Renal mucormycosis following COVID-19 treatment with immune modulators: a case report


Mucormycosis is an opportunistic fungal infection that occurs primarily in immunocompromised individuals, usually affecting the rhino-orbital areas followed by the lungs. This case report presents renal mucormycosis in a young man after COVID-19 pneumonia that escalates the need for regular follow-up of COVID-19 patients. Post-COVID-19 fungal infections are on a steep rise, and the increased use of steroids and immune modulators for COVID-19-associated immune dysregulation and cytokine syndrome increases the risk among patients treated for COVID-19.

1. Manesh A, Rupali P, Sullivan MO, Mohanraj P, Rupa V, George B, et al. Mucormycosis- a clinicoepidemiological review of cases over 10 years. Mycoses. 2019;62(4):391-8.
2. Salehi M, Edalatifard M, Taslimi R, Ghiasvand F, Khajavirad N, Mirfazaelian H. Fighting COVID-19: what are the available options? Adv J Emerg Med. 2020;4(2s):e65
3. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1828-38.
4. Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, et al. Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections. Open Forum Infect Dis. 2021;8(6):ofab201.
5. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.
6. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi (Basel). 2020;6(4):265.
7. Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523.
8. Stanford FA, Voigt K. Iron assimilation during emerging infections caused by opportunistic fungi with emphasis on mucorales and the development of antifungal resistance. Genes (Basel). 2020;11(11):1296.
9. Raghavan R, Date A, Bhaktaviziam A. Fungal and nocardial infections of the kidney. Histopathology. 1987;11(1):9-20.
10. Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014;57(3s):85-90.
11. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48(12):1743-51.
12. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944.e9-944.e15.
IssueVol 6 No 1 (2022): Winter (February) QRcode
SectionCase (report / study)
DOI 10.18502/fem.v6i1.7684
Case Reports COVID-19 Immunosuppression Mucormycosis Renal Insufficiency

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Chaudhary D, Behera A, Sharma N. Renal mucormycosis following COVID-19 treatment with immune modulators: a case report. Front Emerg Med. 2021;6(1):e12.


Download data is not yet available.